Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This report describes 33 open-label treatments with the alkaloid ibogaine given for acute heroin withdrawal in non-medical settings. In 25 of the 33 people, visible signs of opioid withdrawal stopped within 24 hours and stayed absent during 72 hours of observation. The authors note the results are from uncontrolled, non-clinical…
Ibogaine is a psychoactive chemical from a West African shrub that some clinics use to help people stop using opioids or stimulants. Small studies, animal research, and many personal reports say a single high dose can cut opioid withdrawal and reduce cravings. For example, one study found 50% of participants…
A descriptive open-label observational study of ibogaine in people with opioid use disorder found the drug can produce clear but reversible heart and nervous-system side effects. Reported effects included QTc prolongation (a change in the heart’s electrical timing), slow heart rate (bradycardia), and severe problems with balance and coordination (ataxia).…
Researchers made new versions of the psychedelic drug ibogaine, called oxa-iboga compounds, by changing part of the chemical structure. In lab tests on human heart cells these new compounds did not show the heart-rhythm risk that ibogaine can cause. In tests with male rats, a single dose or a short…
In 14 people with opioid use disorder who each received a single 10 mg/kg dose of ibogaine, researchers measured blood levels of ibogaine and its metabolites over 24 hours and linked those levels to side effects. They found large differences between people in how fast ibogaine was cleared, and that…
